ロード中...
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. MATERIALS AND METHODS: We analyzed patients trea...
保存先:
| 出版年: | Cancer Res Treat |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Cancer Association
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6473268/ https://ncbi.nlm.nih.gov/pubmed/29898592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.117 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|